Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia without Antifungal Prophylaxis
Publication date: Available online 26 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jessie Signorelli, Matthew Lei, Jenna Lam, Marla Jalbut, Philip C. Amrein, Amir T. Fathi, Gabriela Hobbs, Hanno Hock, Steven Lawrence McAfee, Alyssa R. Letourneau, Rupa Narayan, Andrew Brunner
Authors: Lee JY, Kim HJ, Kwon E, Choi JY, Oh HJ, Kim JS PMID: 33029984 [PubMed]
Publication date: Available online 10 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Thejus T. Jayakrishnan, Veli Bakalov, Zena Chahine, John Lister, Rodney E. Wegner, Santhosh Sadashiv
Authors: Morimoto A, Fujioka Y, Ushiku T, Kurokawa M PMID: 33028779 [PubMed - as supplied by publisher]
We report the rare case of a patient co-existing NS and DLBCL. DLBCL might be pathogenesis of NS; the findings are supported by the presence of MN, an underlying malignancy (DLBCL), and the lack of anti-PLA2R antibodies. Although further investigation is warranted, our case suggests that DLBCL is a possible cause of secondary MN. PMID: 33028760 [PubMed - in process]
Authors: Cáceres-Perkins W, Cabanillas F, San Vicente G, Rivera-Franceschini C, Sobrino-Najul E, Vega-Vázquez LI, Conde-Sterling D Abstract Mucosa-associated lymphoid tissue (MALT) lymphomas are B-cell neoplasms that commonly affect the gastrointestinal (GI) tract, usually the stomach. In most cases, extranodal marginal zone lymphoma (ENMZL) is an indolent disease. Bone marrow involvement is common with MALT lymphoma accompanied by paraproteinemia; such involvement impels disease progression. Here, we present the case of an 82-year-old Hispanic patient with long-standing ENMZL in whom the gastric site...
The aim of our study was to selectively analyze newly diagnosed acute myeloid leukemia patients treated with a hypomethylating agent and establish their risk for developing invasive fungal infections (IFI). We stratified patients into concern for IFI (cIFI) versus no concern, and observed that patients of the male gender and those with underlying chronic obstructive pulmonary disease (COPD) are at higher risk for cIFI, which may prompt clinicians to consider anti-mold prophylaxis in this setting.
The aim of our study was to selectively analyze newly diagnosed patients with acute myeloid leukemia treated with a hypomethylating agent and establish their risk for developing invasive fungal infections (IFIs). We stratified patients into concern for IFI versus no concern, and observed that patients of the male gender and those with underlying chronic obstructive pulmonary disease are at higher risk for concern for IFI, which may prompt clinicians to consider anti-mold prophylaxis in this setting.
Conclusions. ISV is widely used in hematological pts with IFI also in diseases other than acute myeloid leukemia and it is overall well tolerated. ORR to ISV is at least comparable with other antifungal agents. A rec/ref underlying hematological disease impacts both on OS and response to ISV, while having an IFI refractory to other antifungal agents including azoles does not seem to compromise the response to ISV, although this promising result should be confirmed in prospective studies and larger groups of patients.DisclosuresBusca: Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Sp...
CONCLUSIONS: The Delphi method was useful for the classification and stratification of risk factors for IFI-FF in patients with onco-haematological diseases. Identifying key risk factors will contribute to a better management of IFI-FF in this group of patients at high or changing risk. PMID: 28198173 [PubMed - as supplied by publisher]
Conclusions PET/CT scan can help in monitoring treatment efficacy of IFI in AML patient. However, as PET/CT and CT were concordant in 83% of cases (10/12), while in 2 cases PET/CT showed a complete metabolic response in a persistent lung lesion at CT, these preliminary data cannot support a relevant additional role of PET with respect to CT scan; further follow-up and larger studies are needed.